Edwige Lorthiois

Chapter 33. To market, to market - 2002

Publisher Summary This chapter presents an overview of the new therapeutic chemical entities (NCEs) and new therapeutic biological entities (NBEs) introduced in 2002. A significant increase in the number of NCEs and NBEs was observed in 2002. From the 31 NCEs and 2 NBEs launched in the market, the United States market saw 17 new entities introduced, the Japanese market 8, and the European only 6. These drugs originated mostly from Europe (13) and from United Kingdom (8), followed by the United States (11) and Japan (9). Astra Zeneca discovered the highest number of products in 2002 with a total of four new entities, followed by Pharmacia and Glaxo-Smithkline with three compounds discovered, and Merck & Co and Ono Pharmaceuticals with two compounds. Novartis and Pfizer were at the origin of one new molecular entity and marketed or co-marketed two substances. With eight new launches, antiinfectives were the most active therapeutic area. The anticancer field was also well represented with five new drugs launched. In the cardiovascular area, four drugs were introduced. In the field of allergic and respiratory diseases, three NCEs were marketed. The antiinflammatory field was represented by three COX-2 inhibitors.